Activity Overview
This online, on-demand virtual symposium brings together renowned experts HR+/HER2– breast cancer. In this educational program, these experts review recent key findings and discuss their potential implications for community oncologists. The program features dynamic discussions, practical insights, and the latest data from pivotal clinical trials. The format is designed to provide actionable, evidence-based guidance specifically tailored to help community-based oncology professionals seamlessly integrate these advances into their everyday practice to optimize patient care.
This educational activity is an archive of the live presentation held on October 30, 2026.
Target Audience
This educational program is directed toward community-based medical oncologists, surgeons, advanced practice providers, nurses, and other health care professionals involved in the treatment of breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Develop biomarker-based diagnostic approaches to assess HR+/HER2-advanced breast cancer progression and identify optimal treatment options
- Assess clinical trial data for current and emerging agents for HR+/HER2– breast cancer and impact on the treatment paradigm for treatment plans
- Implement shared decision-making strategies to optimize adverse event management and enhance treatment adherence in clinical practice
Erika P. Hamilton, MD
Chief Development Officer, Late Phase
Director, Breast Cancer Research
Sarah Cannon Research Institute
Nashville, TN
Disclosures: Advisor, Consultant, Fee for Service Recipient (all payments to institution): Arvinas, AstraZeneca, BeOne Medicines, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo, Gilead Sciences, Halda Therapeutics, Incyclix Bio, IQVIA, Janssen, Jazz Pharmaceuticals, Jefferies LLC, Johnson & Johnson, Lilly, Mersana Therapeutics, Novartis, Pfizer, Precede Biosciences, Pyxis Oncology, Roche/Genentech, Samsung Bioepis, Shorla Pharma, Stemline Therapeutics, Tempus Labs; Grant/Research Funding (all payments to institution): AbbVie, Accutar Biotechnology, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, BeOne Medicines, Bicycle Therapeutics, Biohaven Pharmaceuticals, BioNTech, Compugen, Cullinan, Daiichi Sankyo, Dantari, Day One Biopharmaceuticals, Duality Biologics, Ellipses Pharma, Elucida Oncology, Exelixis, Fujifilm, Genmab, Gilead Sciences, H3 Biomedicine, Iambic Therapeutics, ImmunoGen, Inspirna, InventisBio, Jacobio, Jazz Pharmaceuticals, K-Group Beta, Kind Pharmaceuticals, Lilly, Loxo Oncology, MabSpace Biosciences, Mabwell Bioscience, Marengo Therapeutics, MediLink Therapeutics, Merck, Mersana, Novartis, Olema, Orinove, Orum Therapeutics, Pfizer, Pionyr Immunotherapeutics, Prelude Therapeutics, ProfoundBio, Regeneron, Relay Therapeutics, Rgenix, Roche/Genentech, Seagen, Shattuck Labs, Simcha Therapeutics, Stemline Therapeutics, Sutro, SystImmune, Taiho, Tesaro, TheRas, Treadwell Therapeutics, Verastem, Xadcera Biopharmaceutical, Zymeworks
Katherine Sanchez, MD
Breast Medical Oncologist
New Mexico Cancer Center
Albuquerque, NM
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Exigent Research, Gilead Sciences, Lilly; Grant/Research Funding: AstraZeneca, Daiichi Sankyo, Gilead Sciences, Merck, Pfizer, Roche/Genentech, Stemline; Employee: Exigent Research
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.